An overview of how toxicity concerns are balanced with the goal of achieving adequate response in patients with myelofibrosis who receive sequential therapies such as JAK inhibitors.
Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
Follow up and Clinical Workup at 3 Months:
Follow up and Clinical Workup at 6 Months:
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More